ArticleJournal of pain research2026
Rethinking the Boundaries of Local Anesthetic Systemic Toxicity in the Era of Sustained-Release Formulations.
Article in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sustained-release local anesthetic formulations introduce prolonged and dynamic exposure patterns that challenge current frameworks for assessing local anesthetic systemic toxicity (LAST). Recent pharmacovigilance findings, pharmacokinetic evidence, and reports of delayed and recurrent LAST further support the need to re-evaluate LAST across three conceptual boundaries. First, the exposure boundary challenges the use of recommended maximum doses as stand-alone safety thresholds. Co-administration, formulation stability, and the local tissue microenvironment may influence drug release and systemic exposure. Second, the temporal boundary emphasizes that a lower initial peak plasma concentration does not necessarily imply a shorter window of vulnerability, particularly when systemic exposure is prolonged or follows a bimodal pattern. Third, the resuscitation endpoint boundary highlights that return of spontaneous circulation (ROSC) does not necessarily indicate resolution of the underlying toxicological process, as hemodynamic instability may recur after initial ROSC. Assessment of LAST associated with sustained-release formulations should not be limited to administered dose or peak plasma concentration but should consider the entire exposure trajectory. Future guidelines should also define long-term monitoring windows, specific triggers for continuous infusion of lipid emulsion, and safe upper limits for lipid emulsion dosing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.